Virax Biolabs (VRAX) Short term Debt (2023 - 2026)
Virax Biolabs (VRAX) posted quarterly Short term Debt of $28477.0 for Q1 2026, down 12.29% year-over-year from $32468.0 in Q1 2025, and down 12.29% quarter-over-quarter from $32468.0 in Q1 2025.
Virax Biolabs (VRAX) Short term Debt (2023 - 2026) Analysis & Trends
Virax Biolabs' Short term Debt history runs 3 years deep, the most recent figure standing at $28477.0 for Q1 2026.
- In Q1 2026, Short term Debt fell 12.29% year-over-year to $28477.0; the TTM figure through Mar 2026 stood at $28477.0 (down 12.29% YoY), while the FY2026 annual figure was $28477.0, down 12.29% from the prior year.
- Short term Debt for Q1 2026 stood at $28477.0, down from $32468.0 in the prior quarter.
- The five-year high for Short term Debt was $146250.0 in Q1 2023, with the low at $28477.0 in Q1 2026.
- The 3-year median for Short term Debt is $32468.0 (2025), against an average of $69065.0.
- Peak annual rise in Short term Debt reached 12.29% in 2026, while the deepest fall reached 12.29% in 2026.
- Virax Biolabs' Short term Debt stood at $146250.0 in 2023, then sank by 77.8% to $32468.0 in 2025, then decreased by 12.29% to $28477.0 in 2026.
- Business Quant data shows VRAX's Short term Debt at $28477.0 in Q1 2026, $32468.0 in Q1 2025, and $146250.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Virax Biolabs | 1.31 Mn | -5.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28,477.00 |
| Mar 31, 2025 | 32,468.00 |
| Mar 31, 2023 | 146,250.00 |